Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Finished Goods (2022 - 2025)

Gyre Therapeutics (GYRE) has disclosed Finished Goods for 4 consecutive years, with $2.9 million as the latest value for Q4 2025.

  • Quarterly Finished Goods rose 10.71% to $2.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.9 million through Dec 2025, up 10.71% year-over-year, with the annual reading at $2.9 million for FY2025, 10.71% up from the prior year.
  • Finished Goods for Q4 2025 was $2.9 million at Gyre Therapeutics, down from $3.3 million in the prior quarter.
  • The five-year high for Finished Goods was $3.4 million in Q2 2025, with the low at $1.4 million in Q4 2023.
  • Average Finished Goods over 4 years is $2.3 million, with a median of $2.2 million recorded in 2024.
  • The sharpest move saw Finished Goods dropped 2.43% in 2023, then soared 122.77% in 2025.
  • Over 4 years, Finished Goods stood at $1.4 million in 2022, then decreased by 2.43% to $1.4 million in 2023, then surged by 91.5% to $2.6 million in 2024, then grew by 10.71% to $2.9 million in 2025.
  • According to Business Quant data, Finished Goods over the past three periods came in at $2.9 million, $3.3 million, and $3.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.